[Determinants of health-related quality of life in systemic lupus erythematosus: a monocentric, retrospective long-term observational study in Germany].

Determinanten gesundheitsbezogener Lebensqualität bei systemischem Lupus erythematodes: eine monozentrische, retrospektive Langzeitobservationsstudie in Deutschland.
Antimalarial agents Fatigue Glucocorticoids Health-related quality of life Mental component summary Physical component summary SF-36 Systemic lupus erythematosus

Journal

Zeitschrift fur Rheumatologie
ISSN: 1435-1250
Titre abrégé: Z Rheumatol
Pays: Germany
ID NLM: 0414162

Informations de publication

Date de publication:
Nov 2019
Historique:
pubmed: 31 8 2019
medline: 28 11 2019
entrez: 31 8 2019
Statut: ppublish

Résumé

Improvement of health-related quality of life (HRQoL) is a prioritized treatment target in systemic lupus erythematosus (SLE). A retrospective chart review of patients with repeated HRQoL measurements from the outpatient department was conducted in order to better understand which factors drive HRQoL in established SLE. Of particular interest was the association between HRQoL and disease activity. The medical outcomes study short form 36 (SF-36), systemic lupus activity measure (SLAM) and routine clinical data of 169 patients (83% female, mean age 40.3 ± 13 years, disease duration 9.4 ± 7 years) over an average of 7.1 ± 4.2 years were available for analysis by linear mixed modelling. Factors associated with the physical component summary (PCS) and mental component summary (MCS) of the SF-36 were assessed. The proportion of HRQoL which could be explained by the variables was estimated by marginal R At baseline, SLE patients showed a reduced HRQoL in all subscales of the SF-36 including PCS and MCS with the exception of vitality. A higher PCS over time was significantly associated with concurrent parameters, such as intake of antimalarial drugs, no glucocorticoid use, less fatigue, lower disease activity as well as to the baseline parameters of younger age and higher PCS (mR The use of antimalarial drugs and no glucocorticoid intake as well as low current disease activity are modifiable factors associated with a better physical HRQoL. The mental component of HRQoL was poorly represented by conventional parameters and not associated with parameters of disease activity in the present study cohort.

Sections du résumé

BACKGROUND BACKGROUND
Improvement of health-related quality of life (HRQoL) is a prioritized treatment target in systemic lupus erythematosus (SLE). A retrospective chart review of patients with repeated HRQoL measurements from the outpatient department was conducted in order to better understand which factors drive HRQoL in established SLE. Of particular interest was the association between HRQoL and disease activity.
METHODS METHODS
The medical outcomes study short form 36 (SF-36), systemic lupus activity measure (SLAM) and routine clinical data of 169 patients (83% female, mean age 40.3 ± 13 years, disease duration 9.4 ± 7 years) over an average of 7.1 ± 4.2 years were available for analysis by linear mixed modelling. Factors associated with the physical component summary (PCS) and mental component summary (MCS) of the SF-36 were assessed. The proportion of HRQoL which could be explained by the variables was estimated by marginal R
RESULTS RESULTS
At baseline, SLE patients showed a reduced HRQoL in all subscales of the SF-36 including PCS and MCS with the exception of vitality. A higher PCS over time was significantly associated with concurrent parameters, such as intake of antimalarial drugs, no glucocorticoid use, less fatigue, lower disease activity as well as to the baseline parameters of younger age and higher PCS (mR
CONCLUSION CONCLUSIONS
The use of antimalarial drugs and no glucocorticoid intake as well as low current disease activity are modifiable factors associated with a better physical HRQoL. The mental component of HRQoL was poorly represented by conventional parameters and not associated with parameters of disease activity in the present study cohort.

Identifiants

pubmed: 31468165
doi: 10.1007/s00393-019-00691-4
pii: 10.1007/s00393-019-00691-4
doi:

Types de publication

Journal Article

Langues

ger

Sous-ensembles de citation

IM

Pagination

813-819

Références

Lupus Sci Med. 2014 Jun 26;1(1):e000031
pubmed: 25396065
J Rheumatol. 2000 Jun;27(6):1414-20
pubmed: 10852263
RMD Open. 2019 Jun 11;5(2):e000916
pubmed: 31275608
Ann Rheum Dis. 2019 Jun;78(6):736-745
pubmed: 30926722
Lupus. 2000;9(5):322-7
pubmed: 10878722
Ann Rheum Dis. 2014 Jun;73(6):958-67
pubmed: 24739325
Arthritis Care Res (Hoboken). 2019 Jun;71(6):811-821
pubmed: 30055091
Lupus. 2004;13(12):924-6
pubmed: 15645747
Lupus. 2010 Dec;19(14):1606-13
pubmed: 20829309
J Rheumatol. 1997 Nov;24(11):2145-8
pubmed: 9375874
Arthritis Rheum. 1997 Jan;40(1):47-56
pubmed: 9008599
Expert Rev Clin Immunol. 2018 Nov;14(11):915-931
pubmed: 30266076
J Clin Epidemiol. 1998 Nov;51(11):903-12
pubmed: 9817107
Arthritis Rheum. 2004 Jun 15;51(3):465-74
pubmed: 15188335
Presse Med. 2014 Jun;43(6 Pt 2):e197-207
pubmed: 24791601

Auteurs

S Vordenbäumen (S)

Medizinische Fakultät, Poliklinik und Funktionsbereich Rheumatologie & Hiller-Forschungszentrum Rheumatologie, Heinrich-Heine-Universität Düsseldorf, Merowingerplatz 1a, 40225, Düsseldorf, Deutschland. stefan.vordenbaeumen@med.uni-duesseldorf.de.

R Brinks (R)

Medizinische Fakultät, Poliklinik und Funktionsbereich Rheumatologie & Hiller-Forschungszentrum Rheumatologie, Heinrich-Heine-Universität Düsseldorf, Merowingerplatz 1a, 40225, Düsseldorf, Deutschland.

O Sander (O)

Medizinische Fakultät, Poliklinik und Funktionsbereich Rheumatologie & Hiller-Forschungszentrum Rheumatologie, Heinrich-Heine-Universität Düsseldorf, Merowingerplatz 1a, 40225, Düsseldorf, Deutschland.

G Chehab (G)

Medizinische Fakultät, Poliklinik und Funktionsbereich Rheumatologie & Hiller-Forschungszentrum Rheumatologie, Heinrich-Heine-Universität Düsseldorf, Merowingerplatz 1a, 40225, Düsseldorf, Deutschland.

G Lozitiello-Kiroudis (G)

Medizinische Fakultät, Poliklinik und Funktionsbereich Rheumatologie & Hiller-Forschungszentrum Rheumatologie, Heinrich-Heine-Universität Düsseldorf, Merowingerplatz 1a, 40225, Düsseldorf, Deutschland.

H Acar (H)

Medizinische Fakultät, Poliklinik und Funktionsbereich Rheumatologie & Hiller-Forschungszentrum Rheumatologie, Heinrich-Heine-Universität Düsseldorf, Merowingerplatz 1a, 40225, Düsseldorf, Deutschland.

J Richter (J)

Medizinische Fakultät, Poliklinik und Funktionsbereich Rheumatologie & Hiller-Forschungszentrum Rheumatologie, Heinrich-Heine-Universität Düsseldorf, Merowingerplatz 1a, 40225, Düsseldorf, Deutschland.

R Fischer-Betz (R)

Medizinische Fakultät, Poliklinik und Funktionsbereich Rheumatologie & Hiller-Forschungszentrum Rheumatologie, Heinrich-Heine-Universität Düsseldorf, Merowingerplatz 1a, 40225, Düsseldorf, Deutschland.

M Schneider (M)

Medizinische Fakultät, Poliklinik und Funktionsbereich Rheumatologie & Hiller-Forschungszentrum Rheumatologie, Heinrich-Heine-Universität Düsseldorf, Merowingerplatz 1a, 40225, Düsseldorf, Deutschland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH